Understanding pain in women with polyendocrine metabolic ovarian syndrome: health risks and treatment effectiveness
Abstract
Background: Polycystic ovary syndrome (PCOS), recently renamed as polyendocrine metabolic ovarian syndrome (PMOS), is a prevalent endocrine disorder in women, often accompanied by various symptoms, including significant pain, such as dysmenorrhea, abdominal, and pelvic pain, which remains underexplored.
Methods: This retrospective study examines electronic health records (EHR) data to assess the prevalence of pain in women with PMOS. Conducted in January 2026, using data from 120 Health Care Organizations within the TriNetX Global Network, the study involved 103,675,738 women from diverse racial backgrounds. The analysis focused on the prevalence of pain among women with PMOS, both overall and in those prescribed PMOS-related medications. Relative risk ratios (RR) were calculated for future health outcomes and stratified by self-reported race.
Results: The study found that 20.67% of women with PMOS experienced pain, with the highest prevalence among Black or African American (32.70%) and White (30.78%) populations. Both the PMOS and PMOS and Pain cohorts exhibited increased RR for various health conditions, with significant differences noted across racial groups for infertility, ovarian cysts, obesity, and respiratory diseases. Additionally, women with PMOS who were treated with PMOS-related medications showed a decrease in pain diagnoses following treatment.
Conclusions: This study highlights the critical need to address pain in the diagnosis and management of PMOS due to…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 675,738 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.